Zomedica Pharmaceuticals Corp Stock Performance
| ZOM Stock | USD 0.13 0.00 0.00% |
On a scale of 0 to 100, Zomedica Pharmaceuticals holds a performance score of 4. The firm maintains a market beta of 0.32, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Zomedica Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Zomedica Pharmaceuticals is expected to be smaller as well. Please check Zomedica Pharmaceuticals' jensen alpha, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to make a quick decision on whether Zomedica Pharmaceuticals' historical returns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Zomedica Pharmaceuticals Corp are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Zomedica Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Zomedica Corp Q2 2024 Earnings Call Highlights Diagnostics Surge Amid Revenue Challenges | 10/09/2024 |
2 | Acquisition by Ann Cotter of 8333 shares of Zomedica Pharmaceuticals at 0.11 subject to Rule 16b-3 | 10/14/2024 |
3 | ZOM - Zomedica Corp. Latest Stock News Market Updates - StockTitan | 10/24/2024 |
4 | Acquisition by Anthony Blair of 150000 shares of Zomedica Pharmaceuticals at 0.123 subject to Rule 16b-3 | 11/08/2024 |
5 | Acquisition by Russell Klass of 210200 shares of Zomedica Pharmaceuticals at 0.12 subject to Rule 16b-3 | 11/11/2024 |
6 | Acquisition by Robert Cohen of 1823107 shares of Zomedica Pharmaceuticals at 0.13 subject to Rule 16b-3 | 11/13/2024 |
| Begin Period Cash Flow | 27.4 M |
Zomedica |
Zomedica Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 12.00 in Zomedica Pharmaceuticals Corp on September 4, 2024 and sell it today you would earn a total of 1.00 from holding Zomedica Pharmaceuticals Corp or generate 8.33% return on investment over 90 days. Zomedica Pharmaceuticals Corp is generating 0.2052% of daily returns assuming volatility of 4.035% on return distribution over 90 days investment horizon. In other words, 35% of stocks are less volatile than Zomedica, and above 96% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Zomedica Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zomedica Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zomedica Pharmaceuticals Corp, and traders can use it to determine the average amount a Zomedica Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0509
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ZOM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.04 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Zomedica Pharmaceuticals is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zomedica Pharmaceuticals by adding it to a well-diversified portfolio.
Zomedica Pharmaceuticals Fundamentals Growth
Zomedica Stock prices reflect investors' perceptions of the future prospects and financial health of Zomedica Pharmaceuticals, and Zomedica Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zomedica Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0929 | ||||
| Profit Margin | (2.15) % | ||||
| Operating Margin | (1.48) % | ||||
| Current Valuation | 50.64 M | ||||
| Shares Outstanding | 997.95 M | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 4.80 X | ||||
| Revenue | 25.19 M | ||||
| Gross Profit | 13.65 M | ||||
| EBITDA | (29.39 M) | ||||
| Net Income | (34.53 M) | ||||
| Cash And Equivalents | 27.4 M | ||||
| Cash Per Share | 0.19 X | ||||
| Total Debt | 2.73 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 43.50 X | ||||
| Book Value Per Share | 0.24 X | ||||
| Cash Flow From Operations | (15.97 M) | ||||
| Earnings Per Share | (0.06) X | ||||
| Market Capitalization | 147.6 M | ||||
| Total Asset | 253.2 M | ||||
| Retained Earnings | (170.93 M) | ||||
| Working Capital | 90.85 M | ||||
About Zomedica Pharmaceuticals Performance
By examining Zomedica Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Zomedica Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Zomedica Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 237.66 | 225.78 | |
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.13) | (0.14) | |
| Return On Assets | (0.14) | (0.14) | |
| Return On Equity | (0.14) | (0.15) |
Things to note about Zomedica Pharmaceuticals performance evaluation
Checking the ongoing alerts about Zomedica Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zomedica Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zomedica Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Zomedica Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 25.19 M. Reported Net Loss for the year was (34.53 M) with profit before taxes, overhead, and interest of 13.65 M. | |
| Zomedica Pharmaceuticals Corp has about 27.4 M in cash with (15.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Zomedica Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Robert Cohen of 1823107 shares of Zomedica Pharmaceuticals at 0.13 subject to Rule 16b-3 |
- Analyzing Zomedica Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zomedica Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Zomedica Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zomedica Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zomedica Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zomedica Pharmaceuticals' stock. These opinions can provide insight into Zomedica Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.